Biographical Sketches of Course Directors and Presenting
Faculty (A - L)
JULES ANGST, M.D.
Epidemologic Research
Zurich University Psychiatric Hospital
Zurich, Switzerland
Jules Angst is Emeritus Professor of Zurich University,
Honorary Doctor of Heidelberg University and Past-President of the Association
of European Psychiatrists.
A graduate of Zurich University Medical School in 1952; he was
appointed lecturer in Clinical Psychiatry in 1966; Assistant Professor in 1967;
Professor of Clinical Psychiatry in 1969 and Head of the Research Department of
Psychiatric University Hospital 1969-1994.
Jules Angst has received many awards in recognition of his
work: Anna Monika Awards (1967/1969), Otto Naegeli Prize (1983), Emil Kraepelin
Medal in gold, Max Planck Institute, Munich (1992); Selo Prize NARSAD /
Depression Research, USA (1994).
He is an Honorary Fellow of Royal College of Psychiatrists, Mexican, Chilean,
Polish and Austrian Psychiatric Associations, Swiss Society of Psychiatric
Epidemiology, German Association of Biological Psychiatrists, American
Psychopathological Association, European College of Neuropsychopharmacology,
Swiss Society of Biological Psychiatry, European College for Study Methods in
Clinical Trials, Association of European Psychiatrists.
DAVID AXELSON, M.D.
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Director, Child and Adolescent Bipolar Service
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
David Axelson, M.D., is the Medical Director, Child and Adolescent Bipolar
Services (CABS), Western Psychiatric Institute and Clinic (WPIC). Dr. Axelson
earned his medical degree at Duke University and completed his general and child
psychiatric training at University of Pittsburgh – WPIC. He completed a
post-doctoral research fellowship in child and adolescent mood disorders at
University of Pittsburgh – WPIC and has been on faculty as an Assistant
Professor since April 2000. He has been medical director of CABS for the past
year and his research focus is the assessment and treatment of pediatric bipolar
disorder.
MARK S. BAUER, M.D.
Acting Chief of Staff and Chief
Mental Health and Behavioral Sciences Service
Providence VA Medical Center
Associate Professor of Psychiatry
Brown University School of Medicine
Providence, Rhode Island
Dr. Bauer received his B.A. from the University of Chicago and
his M.D. from the University of Pennsylvania. He is currently Associate
Professor of Psychiatry at Brown University and on staff at the Providence (RI)
Veterans Affairs Medical Center.
Dr. Bauer has served as Principal Investigator on federal
grants each year since his fellowship and has received awards for research,
administration, and clinical care including twice being named Exemplary
Psychiatrist by the National Alliance for the Mentally Ill.
Dr. Bauer’s main scientific contributions include: (a) use of
high dose thyroid hormone treatment for rapid cycling bipolar disorder; (b)
assessment, phenomenology, and course in bipolar disorder; and (c) controlled
trials of methods to improve treatment delivery in bipolar disorder.
BORIS BIRMAHER, M.D.
Associate Professor of Psychiatry
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Dr. Birmaher is the co-director of the Children and Adolescent
Bipolar Clinic, University of Pittsburgh Medical Center. He has conducted
research in the clinical presentation, longitudinal outcome, biology, and
pharmacological and psychosocial treatments of children and adolescents with
major depressive, bipolar, and anxiety disorders. In addition, he has developed
psychiatric interviews and ratings scales for the assessment of children with
mood and anxiety disorders. Dr. Birmaher has received support from the National
Institute of Mental Health to fund his research for adolescents with bipolar
disorders and also children of bipolar parents. He has published many articles
and book chapters related to mood and anxiety disorders in children and
adolescents. Dr. Birmaher is a member of the editorial board of the Journal of
the American Academy of Child and Adolescent Psychiatry and he serves as
editorial consultant to several journals including the American Journal of
Psychiatry, Archives of General Psychiatry, and Biological Psychiatry. In
addition to his research, Dr. Birmaher teaches and supervises residents, medical
students and fellows from other countries, and provides treatment to an
extensive patient population. He has twice been the recipient of the Golden
Apple Award for teaching at WPIC, received an award for clinical excellence
while a resident in child psychiatry, and numerous awards for research. Recently
he was named “Health Care Hero” by the Pittsburgh Business Times for his work
with bipolar children and their parents.
GIOVANNI BATTISTA CASSANO, M.D.
Professor of Psychiatry
University of Pisa School of Medicine
Department of Psychiatry, Neurobiology, Pharmacology, and
Biotechnology
University of Pisa
Pisa, Italy
Giovanni Battista Cassano is Full Professor of the School of
Medicine, University of Pisa, Italy since 1978. He is also a fellow of The Royal
College of Psychiatrists, member of the American Psychopathological Association
and of the Geselleschaft Osterreichischer Nervenarzte und Psychiater. He was
founder of The International Committee for Prevention and Treatment of
Depression and foreign corresponding member of the American College of
Neuropsychopharmacology (ACNP) since 1995, and member of the European College of
Neuropsychopharmacology (ECNP) since 1987.
His scientific background moves from basic to clinical
psychopharmacology, with special regard to the methodological aspects of
clinical trials with psychoactive drugs. Thanks to his contribution in this
area, Professor Cassano obtained a 6-year grant (from 1980-1986) from the
“National Institute of Mental Health”.
Professor Cassano conducted and coordinated a large number of
clinical studies, to test the efficacy and safety of antidepressants,
anxiolitics, antipsychotics, and mood stabilizers. He is dedicated to research
in different psychopathological and clinical areas, with special interest in the
diagnosis, classification, and short-term/long-term treatment of mental
disorders.
In the last 5 years, Professor Cassano has lead an
international group of clinical researchers (‘Spectrum Project’, involving the
University of Pisa, the Western Psychiatric Institute of Pittsburgh, the
Columbia University of New York, and the University of California-San Diego),
for the assessment of sub-clinical, soft, and atypical manifestations of
bipolar, anxiety, and eating disorders. Along this collaboration, structured
interviews for the evaluation and the assessment of sub-threshold manifestations
of mood (SCI-MOODS™), panic (SCI-PAS™), eating (SCI-ABS™), obsessive-compulsive
(SCI-OBS™), social-phobic (SCI-SHY™), post-traumatic stress disorders (SCI-PTSD™),
and substance abuse (SCI-SUB™) have been developed.
Professor Cassano is author of over 500 scientific
publications on nosology, diagnosis and treatment of psychiatric disorders.
Moreover, he is co-author of a best-selling book for the Italian public.
Professor Cassano is currently Chief of the Department of
Psychiatry, University of Pisa, where he is leading a group of researchers and
clinicians, who have combined expertise both in academic and clinical
psychiatry, advancing the understanding of the ‘spectrum’ concept in mood,
anxiety and eating disorders.
PAULA J. CLAYTON, M.D.
Clinical Professor of Psychiatry
University of New Mexico School of Medicine
Albuquerque, New Mexico
Professor Emeritus
Department of Psychiatry
University of Minnesota Medical School
Minneapolis, Minnesota
Dr. Paula Clayton attended the University of Michigan where
she received a Bachelor of Science degree in 1956. She graduated AOA from
Washington University School of Medicine in St. Louis, Missouri in 1960. After
an internship, she took her psychiatry residency at Washington University. She
became an instructor and chief resident in 1965/66. Thereafter, she joined the
faculty and progressed from an assistant professor to associate to full
professor in 1976. In July of 1981 she moved to Minnesota to become Professor
and Head of the Department of Psychiatry. In 1969 she published, with Drs.
Winokur and Reich, the first textbook on mania, entitled Manic Depressive
Illness. She has published three additional books, 150 papers in refereed
journals, and 20 book chapters. Her areas of expertise and research are mood
disorders, particularly bipolar and unipolar disorders, and bereavement. She
continues to write in these areas.
She is a Fellow in the American Psychiatric Association and a
member of the American Psychopathological Association, the American College of
Neuropsychopharmacology, and the Society of Biological Psychiatry. She was on
the DSM-III Task Force for Nomenclature and Statistics. She has been the
President of the American Psychopathological Association, Psychiatric Research
Society, and Society of Biological Psychiatry. She is on editorial boards, has
been a panel member for AAMC, for the Institute of Medicine, and for the VA
Medical Centers. She was a member of the National Board of Medical Examiners
Psychiatry Test Committee and a member of the FDA. In 1985, she received the
Athena Award from the University of Michigan for being the outstanding woman
alumna of the year. She also received a Distinguished Alumnae Award in 1985 from
Washington University and in 1993 the First Aphrodite Jannopaulo Hofsommer Award
from Washington University.
RODNEY ELGIE
President, GAMIAN-Europe
Kent, United Kingdom
Rodney Elgie is aged 56 and trained as a solicitor in the
later half of 1960’s, and remained in private practice for over 20 years, rising
to the position of senior partner of the firm for his last six years.
Having suffered from clinical depression in the late
1980’s/early 1990’s, he joined Depression Alliance on a voluntary basis in 1994
and became its first paid staff member a year later. Elgie was responsible for
overseeing the substantial growth of the charity over the next five years so
that it is now clearly established as the UK’s leading organization within the
field of depression with four major regional offices.
In the autumn of 1999, Elgie took on the role of European
Development Director for GAMIAN-Europe (Global Alliance of Mental Illness
Advocacy Networks), which is Europe’s principal patient driven federation and
today has 43 national association members from 22 European countries and
associate members from the other continents. The registered charity covers all
aspects of mental illness including schizophrenia, bipolar disorder, clinical
depression, obsessive compulsive disorders, phobia and anxiety. In October,
2000, Elgie was elected President of GAMIAN-Europe and now works to raise the
profile and importance of mental health among members of the European Parliament
and the European Commission. He maintains collaborative working with the
Hungarian, Lithuanian and Ukrainian Nursing Associations within the field of
mental health, is currently working with the Central Association of Psychiatry
in Moscow to develop a training package for potential self-help group leaders
for people with a mental illness. On behalf of the European Commission, Elgie is
undertaking a major literature review on suicide and parasuicide across Europe
and will shortly commence work on investigating the health, social, financial,
cultural, and welfare problems experienced by women over the age of 65 on a pan
European basis.
Elgie was from 1997 until the 17th January, 2001, the UK’s
Board representative of the International Alliance of Patient Organizations. He
is currently a member of the Scientific Committee of the Mental Health
Foundation in London and the Royal College of Psychiatrist’s Patients and Carers
Liaison Committee, a board member of the Health Coalition Initiative in the UK
and an expert panel member on various national and international bodies,
including pharmaceutical companies.
He has written numerous articles on mental health and men’s
health from the patient’s perspective, is a frequent contributor to BBC’s radio
programs on mental health and speaks at numerous health conferences and
congresses both in the UK and internationally.
ELLEN FRANK, Ph.D.
Professor of Psychiatry and Psychology
University of Pittsburgh School of Medicine
Director, Depression and Manic Depression Prevention Program
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Dr. Ellen Frank is Professor of Psychiatry and Psychology at
the University of Pittsburgh School of Medicine and Director of the Depression
and Manic Depression Prevention Program at Western Psychiatric Institute and
Clinic. She graduated from Vassar College in 1966 and received a masters’ degree
in English from Carnegie Mellon University in 1967. Her doctoral work in
psychology was done at the University of Pittsburgh and completed in 1979.
Under a MERIT Award grant from the National Institute of
Mental Health, Dr. Frank is currently studying the efficacy of Interpersonal and
Social Rhythm Therapy, a psychotherapy she and her colleagues developed for the
treatment of manic-depressive illness. It is intended as an adjunct to
appropriate pharmacotherapy. She is also conducting an NIMH-sponsored study of
women with recurrent depression in which she hopes to sort out how biology, life
stress, and different “doses” of psychotherapy interact in increasing or
decreasing vulnerability to new episodes of depression. In addition, Dr. Frank
is currently involved in a project based at the University of Pisa, Italy aimed
at achieving a better understanding of the clinical importance of subsyndromal
mood, anxiety and eating disorders.
An expert in mood disorders and their treatment, Dr. Frank was
a member of the American Psychiatric Association Task Force on DSM-IV and was
Chair of the Food and Drug Administration Psychopharmacologic Drugs Advisory
Panel. Dr. Frank is currently a member of the National Advisory Mental Health
Council and the National Institute of Health Panel on Scientific Boundaries for
Review. Dr. Frank also serves as Chair of the American College of
Neuropsychopharmacology’s Ethics Committee. She is an Honorary Fellow of the
American Psychiatric Association. In 1999, Dr. Frank was elected to the National
Academy of Sciences Institute of Medicine.
BARBARA GELLER, M.D.
Professor of Psychiatry
Washington University School of Medicine in St. Louis
St. Louis, Missouri
Dr. Geller is a Professor of Psychiatry at Washington
University School of Medicine in St. Louis where she is principal investigator
on NIMH funded grants to study the diagnosis, longitudinal course, psychosocial
functioning and family psychopathology of prepubertal children and early
adolescents who have bipolar disorders. She has published over 95 articles on
childhood mania and on the psychopharmacology and longitudinal course of
prepubertal major depressive disorders. Dr. Geller has served on and chaired
numerous federal advisory committees at the NIMH, NIDA and FDA and is on
multiple editorial boards. Dr. Geller is the recipient of the American Academy
of Child and Adolescent Psychiatry Nathan Cummings Special Research Award, the
NAMI Exemplary Scientist Award and the St. Louis AMI Outstanding Scientist
Award. She has served on the Board of Directors of the St. Louis DMDA and is
currently on the Board of Directors of the Child and Adolescent Bipolar
Foundation.
VALENTIM GENTIL, M.D., Ph.D.
Professor of Psychiatry, University of São Paulo Medical
School
Chairman, Institute of Psychiatry, Hospital das Clínicas
São Paulo, Brazil
Dr. Gentil completed his medical studies and residency in
Psychiatry at the Department and Institute of Psychiatry in São Paulo, and then
was a post-graduate student at the Institute of Psychiatry and Maudsley Hospital
in London, UK, where he obtained his PhD in Clinical Psychopharmacology under
the supervision of Professor Malcolm Lader. Back to Brazil, Dr.Gentil was
assistant and then associate professor in the Departments of Pharmacology (until
1987) and Psychiatry (1986-current) of the University of São Paulo. His
teaching, clinical and reseach activities include work in the areas of
diagnosis, treatment and psychophysiology of mood and affective disorders. He
was Head of the Department of Psychiatry in 1992-96, and since 1994 he is
Professor and Chairman fo the Institute of Psychiatry, a 200 bed academic
psychiatric complex within the 2000 bed medical centre of the USP Medical
School. His current interests include a collaborative investigation of the
psychobiological mechanisms of emotional response regulation and appetite/weight
control under antidepressants, and the development of an efficient program for
bipolar disorder prevention. He has published 62 articles in peer-reviewed
journals and is a member of the editorial boards of Bipolar Disorder, Molecular
Psychiatry, Journal of Psychopharmacology, and Stress Medicine, among other
scientific journals. Besides his academic and clinical activities, Dr.Gentil
serves in the advisory board of ABRATA - Brazilian Association of Affective
Disorders, a non-professional organization.
EARL L. GILLER, Jr., M.D., Ph.D.
Senior Director, CNS Clinical Development
Pfizer Global Research and Development
Groton, Connecticut
Adjunct Associate Professor of Psychiatry
Yale School of Medicine
New Haven, Connecticut
Dr. Giller is a senior leader in the CNS therapeutic area at
Pfizer, Inc., responsible for phase II and III clinical trials in the
development of new psychotropic medications. He contributed to the development
of sertraline (Zoloft) for post-traumatic stress disorder and to ziprasidone (Geodon)
for schizophrenia. He is currently leading the clinical team in the development
of a new antidepressant. Before coming to industry, Dr. Giller conducted
research in monoamine oxidase activity, post-traumatic stress disorder,
neuroendocrinology and the pharmacologic treatment of schizophrenia, mood and
anxiety disorders, with publications in all of these areas. He has been funded
by the VA through Career Development and Merit Review awards, and by NIMH. He
has served as a grant reviewer for the VA and NIMH. In addition to research, Dr.
Giller has run both inpatient and outpatient programs.
GIOVANNI De GIROLAMO, M.D.
Coordinator
National Institute of Health
National Mental Health Project
Rome, Italy
Giovanni de Girolamo was born in Naples (Italy) on April 3,
1953. He graduated in 1977 from the 2nd Medical School, University of Naples. In
1981 he completed his residency in Psychiatry at the Institute of Psychiatry of
the 2nd Medical School, University of Naples. He worked at the Departments of
Mental Health in Cremona and Turin (Italy) from 1978 to 1988. In the years
1988-1994 he was appointed initially as Associate Professional Officer and
subsequently as Medical Officer at the Division of Mental Health of the World
Health Organization in Geneva (CH). From 1994 to 1998 he was Consultant
Psychiatrist at the 2nd University Psychiatric Clinic and at the Department of
Mental Health in Bologna (I). From 1998 up to now he has been the Coordinator of
the ‘National Mental Health Project’ at the Italian National Institute of Health
in Rome. He has received fellowships to spend some time as visiting scientist at
the Institute of Psychiatry (London, U.K.), the Institute of Psychiatric
Demography (Aarhus, Denmark) and the Western Psychiatric Institute and Clinic,
Pittsburgh (USA). He has promoted several research activities internationally
and in Italy, and has organized many workshops, seminars and training courses
with international speakers in Italy. He is the author, editor or translator
(into Italian) of 30 books or monographs, of more than 98 papers and 35 book
chapters. He has also lectured extensively.
FREDERICK K. GOODWIN, M.D.
Director
Center on Neuroscience, Medical Progress and Society
Research Professor of Psychiatry
Department of Psychiatry
Director, Psychopharmacology Research Center
George Washington University Medical Center
Washington, DC
Frederick K. Goodwin, M.D., is Research Professor of
Pscyhiatry at the George Washington University and Director of the University’s
Psychopharmacology Research Center where he conducts research on
manic-depressive illness. He also directs the Center on Neuroscience, Medical
Progress, and Society at the George Washinton University Medical Center. At the
Center, Dr. Goodwin’s policy studies focus on the impact of changing patterns of
health care on quality and innovation in medicine.
Dr. Goodwin is the former Director of the National Institute
of Mental Health (NIMH), the largest research and research training institution
in the world dedicated to the application of biological, behavioral, and social
science to the treatment and prevention of mental illness and refinement of
mental health services. Prior to that, he held a Presidential appointment as
head of the Alcohol, Drug Abuse, and Mental Health Administration. A
physician-scientist specializing in psychiatry and psychopharmacology, Dr.
Goodwin served from 1981 to 1988 as NIMH Scientific Director and Chief of
Intramural Research. He joined the NIMH in 1965 and has become an
internationally recognized authority in the research and treatment of major
depression and manic-depressive illness. For example, he was first to report the
antidepressant effects of lithium in a controlled study.
A graduate of Georgetown University, Dr. Goodwin received his
M.D. from St. Louis University, and took his psychiatric residency at the
University of North Carolina in Chapel Hill. He is a Member of the institute of
Medicine of the National Academy of Sciences and a Fellow of the ACNP. He serves
on the editorial boards of key scientific journals, including the Archives of
General Psychiatry, The Journal of Clinical Psychopharmacology and is a founder
of Psychiatry Research.
Dr. Goodwin is a recipient of the major research awards in his
field including the Hofheimer Prize from the American Psychiatric Association,
the International Anna-Monika Prize for Research in Depression, the Edward A.
Strecker Award, the Lieber Prize from NARSAD, the McAlpin Award, the
Distinguished Service Award from NAMI, and the Research Award from the American
Foundation for Suicide Prevention.
He was the first recipient of the Psychiatrist of the Year
from Psychiatric Times, and the Fawcett Humanitatian Award of the NDMDA. In 1998
he was elected President of the Psychiatric Research Society.
The author of 420 publications, Dr. Goodwin (with K.R.
Jamison, Ph.D.) wrote Manic-Depressive Illness, the first psychiatric text to
win the Best Medical Book award from the Association of American Publishers. He
is one of five psychiatrists on the Current Contents list of the most frequently
cited scientists in the world and one of twelve psychiatrists listed in The Best
Doctors in the U.S.
In addition to his work at the George Washington University
Medical Center and his private practice, Dr. Goodwin is the host of the award
winning The Infinite Mind radio show. This one hour national weekly public radio
program is dedicated to issues relating to the mind, the brain, and mental
illness. The program is now carried in more than 150 markets. It’s estimated
500,000+ listeners make it the most popular health show in public radio.
GUY M. GOODWIN, M.D.
W.A.Handley Professor of Psychiatry
University Department of Psychiatry
Warneford Hospital
Oxford, England
Professor Goodwin is W. A. Handley Professor of Psychiatry and
Head of the University department of Psychiatry at the University of Oxford. His
research interests are in the treatment of severe psychiatric illness and the
application of neuroscience in understanding the neurobiology of mood disorder.
Currently, he is involved in projects on the neurobiology and genetics of
vulnerability to mood disorder and the neuropsychology of manic mood
disturbance. He is also developing the basis for a large scale pragmatic
clinical trial in bipolar affective disorder. He has served on the Wellcome
Trust Neurosciences Panel, is president-elect of the British Association for
Psychopharmacology and a non-executive member of the Board of the Oxfordshire
Mental Healthcare NHS Trust.
IAN M. GOODYER, M.D. F.Med.Sci.
Professor of Child and Adolescent Psychiatry
Developmental Psychiatry Section
Department of Psychiatry
Cambridge University
Cambridge, England
Ian M. Goodyer is Professor of Child and Adolescent
Psychiatry, Fellow of Wolfson College and Head of the Developmental Psychiatry
Section in the Department of Psychiatry at the University of Cambridge Clinical
School, England. His research interests have included epidemiological, clinical
and experimental investigations into the role of undesirable life events and
psychoendocrine processes in the onset, maintenance and outcome of unipolar
depressions in young people. He has published three books and over 100 articles
in these areas. He is general editor of the Cambridge Child Psychiatry series
and is also co-director of the Cambridge Language and Speech Project, a 10 year
longitudinal study of children with specific language impairment. He is
Secretary-General of the International Association of Child and Adolescent
Psychiatry. In 1997 he was awarded the Nathan Cummings Foundation Prize by the
American Academy of Child and Adolescent Psychiatry for published research in
the field of depression in young people. In 1999 he was elected to a Fellowship
of the Academy of Medical Sciences of Great Britain.
NOREEN A. REILLY-HARRINGTON, Ph.D.
Instructor in Psychology
Harvard Medical School
Clinical Assistant in Psychology
Massachusetts General Hospital
Department of Psychiatry
Boston, Massachusetts
Noreen A. Reilly-Harrington, PhD is an Instructor in
Psychology at Harvard Medical School and is on the staff of the Harvard Bipolar
Research Program at Massachusetts General Hospital. She is a graduate of
University of Pennsylvania and Temple University. Dr. Reilly-Harrington is a
Founding Fellow of the Academy of Cognitive Therapy and has received research
awards from the Society for Research in Psychopathology, the Association for the
Advancement of Behavior Therapy, and Massachusetts General Hospital for her work
examining the role of life stress and cognition on the course of bipolar mood
disorders. She has lectured both nationally and internationally on the topic of
cognitive behavioral therapy for bipolar disorder and is a Pathway Leader for
the National Institute of Mental Health's Systematic Treatment Enhancement
Program for Bipolar Disorder, the largest study of bipolar disorder ever
conducted. She is also a co-author of a recent book entitled “Bipolar Disorder:
A Cognitive Therapy Approach.”
PAUL HARRISON, M.D., M.R.C.PSYCH.
Reader and Honorary Consultant Psychiatrist
University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom
Paul Harrison, M.D., M.R.C.Psych. received a first class
degree in physiological sciences from Oxford in 1982 and qualified in medicine
in 1985. I trained in psychiatry in Oxford and London, and spent three years as
a research fellow at St. Mary’s Hospital Medical school, London, investigating
gene expression in Alzheimer’s disease. After receiving his research degree, he
returned to Oxford in 1991 as a lecturer and established a laboratory for
molecular psychiatry research. He became a Wellcome Trust Senior Research Fellow
in 1995, a University Reader in 1997, and a Professor in 2000. He has clinical
and teaching duties in addition to running a research group. The research is
directed at molecular, genetic, and neuropathological aspects of schizophrenia
and mood disorder, as well as relevant experimental models. In 1998, he was
awarded the CINP/Paul Janssen Schizophrenia Prize, and in 1999 the British
Association for Psychopharmacology Senior Clinical Psychopharmalogist Prize. He
is on the Editorial Board of Neuroscience and Biological Psychiatry. Research
support is provided by a Centre Award from the Stanley Foundation, and grants
from the Wellcome Trust and the Medical Research Council.
MARTHA HELLANDER
Executive Director
Child and Adolescent Bipolar Foundation
Wilmette, Illinois
Martha Hellander, J.D., of Wilmette, Illinois, began leading
on-line parent support groups on the Internet in 1996. She is co-founder and
executive director of the Child and Adolescent Bipolar Foundation (CABF), a
national, not-for-profit organization of providing information, support and
advocacy for families raising children diagnosed with, or at risk for, bipolar
disorder. CABF’s interactive web site, www.bpkids.org, offers online support
groups, message boards and chat rooms, a support groups database and a database
of professional members to help families in the U.S. and abroad find quality
services and support.
STEVEN E. HYMAN, MD
Director, National Institute of Mental Health
Bethesda, Maryland
Steven E. Hyman, MD is Director of the National Institute of
Mental Health (NIMH), the component of the National Institutes of Health charged
with generating the knowledge needed to understand, treat, and prevent mental
illness. Under Dr. Hyman's leadership, NIMH has heightened the priority it gives
to four broad areas: (1) fundamental research on brain, behavior and genetics;
(2) rapid translation of basic discoveries into research on mental disorders;
(3) research that directly impacts the treatment of individuals with mental
disorders, including clinical trials and studies of treatment and preventive
interventions in “real world” settings; and (4) research on child development
and childhood mental disorders. Dr. Hyman continues to direct an active research
program in molecular neurobiology on the NIH campus (Bethesda, MD), focused on
how neurotransmitters, especially dopamine alter the expression of genes in the
striatum and thereby produce long term changes in neural function that can
influence behavior.
Prior to his position at NIMH, Dr. Hyman was Professor of
Psychiatry at Harvard Medical School and Director of Psychiatry Research at
Massachusetts General Hospital in Boston. He also taught neurobiology at Harvard
Medical School and was the first faculty Director of Harvard University's
Interfaculty Initiative in Mind, Brain, and Behavior. In addition to his
scientific writings, Dr. Hyman has authored and edited several widely used
clinical texts. He serves on several review and advisory boards including the
Riken Brain Sciences Institute in Japan, the Max Planck Institute in Germany,
and the Howard Hughes Medical Institute in the United States. Dr. Hyman received
his BA from Yale in 1974 (summa cum laude), and his MA from the University of
Cambridge in 1976, where he was a Mellon fellow studying the history and
philosophy of science. He received his MD from Harvard Medical School (cum
laude) in 1980. Following an internship in Medicine at Massachusetts General
Hospital (MGH), a residency in psychiatry at McLean Hospital, and a clinical
fellowship in neurology at MGH, he was postdoctoral fellow at Harvard in
molecular biology. Among his many awards and honors, Dr. Hyman is an elected
member of the Institute of Medicine and recipient of the Distinguished Service
Award from the National Alliance for the Mentally Ill.
HILKKA KÄRKKÄINEN
Master of Social Sciences
Helsinki University
Executive Director of AFFINITY
Finnish Central Association for Mental Health
Helsinki, Finland
Mrs. Hilkka Kärkkäinen has been the Executive Director of
AFFINITY since 1998. AFFINITY is a patient organization with 150 local
associations and some 15,000 individual members. Before her present position in
AFFINITY Hilkka Kärkkäinen made a career mainly in the public sector in
municipalities carrying out various duties in social sector for the City of
Helsinki and for the Probation and Prison After Care Association in Helsinki.
The last twelve years before her present job, Hilkka Kärkkäinen was working for
the City of Espoo as an Office Manager. She was elected a President of GAMIAN-Europe
in 1999 and has been a Vice-President since the year 2000.
PAUL E. KECK, JR., M.D.
Professor and Vice Chairman for Research
Deparment of Psychiatry
University of Cincinnati College of Medicine
Cincinnati, Ohio
Paul E. Keck, Jr., MD, is Professor of Psychiatry and
Pharmacology and Vice Chairman for Research, Department of Psychiatry,
University of Cincinnati College of Medicine. Dr. Keck is also Co-Director of
the Biological Psychiatry Program, affiliated with the University of Cincinnati
Medical Center. The Biological Psychiatry Program conducts research regarding
the nosology, biology, course of illness, genetics, and treatment of bipolar
disorder. In addition, the Program is a center for the study of new medicines to
treat mood, anxiety, psychotic, eating, psychosomatic and impulse controls
disorders.
A graduate of Dartmouth College, Dr. Keck received his MD from
the Mount Sinai School of Medicine, New York, NY. He served his internship in
Internal Medicine at the Beth Israel Medical Center in New York and completed
his residency training in Psychiatry at McLean Hospital, Belmont, MA. Dr. Keck
remained on faculty at McLean and Harvard Medical School before joining the
faculty at the University of Cincinnati in 1991.
Dr. Keck is the author of over 350 scientific papers and
abstracts in leading medical journals. He has also contributed over 90 reviews
and chapters to major psychiatric textbooks. Dr. Keck is the editor of the book
Managing Depressive Symptoms in Schizophrenia. He serves on the editorial boards
of 6 journals. He also served on the American Psychiatric Association’s
Workgroup to Develop Practice Guidelines for Treatment of Patients with Bipolar
Disorders and currently serves on the APA Institute for Research and Education.
Dr. Keck is the recipient of numerous honors, including the
Gerald Klerman Young Investigator Award from the National Depressive and
Manic-Depressive Association (NDMDA); the Exemplary Psychiatrist Award from the
National Alliance of the Mentally Ill (NAMI); the Philip Isenberg Teaching Award
from Harvard Medical School; the Nancy C A Roeske Certificate for medical
student education from the American Psychiatric Association; the Wyeth-Ayerst
AADPRT Mentorship Award; two Communicator Awards for Continuing Medical
Education; the Outstanding Physician Partner Award of the Postgraduate Institute
for Medicine; and two Golden Apple Teaching Awards from the University of
Cincinnati College of Medicine.
He is listed as one of the Best Doctors in Cincinnati by
Cincinnati Magazine; The Best Doctors in America, a directory of the top one
percent of physicians in the United States as rated by their peers; and as one
of the nation’s Best Mental Health Experts by Good Housekeeping Magazine. Dr.
Keck is also the Director of Scientific Development for the Neuroleptic
Malignant Syndrome Information Service (NMSIS).
ATHANASIO KOUKOPOULOS, M.D.
Director, Centro Lucio Bini
Chief, Medical Staff
Clinica Belvedere Montello
Rome, Italy
Dr. Koukopoulos is the Director of the Centro Lucio Bini, a
center for the treatment and the study of psychiatric conditions and especially
of affective disorders, that he and other colleagues founded in 1976 and was
Chief of the Medical Staff of the Clinica Belvedere Montello, a psychiatric
in-patient private hospital in Rome, from 1963 to1998.
His main activity is the examination and treatment of
psychiatric patients with a particular interest in Affective Disorders. In
addition to his clinical activity, he has been performing clinical research into
the course of Manic-Depressive Illness and the pattern of the manic-depressive
cycle.
He is also conducting studies on manic-depressive temperament
and its importance in the genesis of affective disorders and their course.
Related to the above issues have been other lines of research,
like the response to prophylactic lithium treatment and the increase of
bipolarity, frequency of recurrences, and mixed states following antidepressant
drug treatments. The temperament, the previous course, and the concomitant
factors of rapid cyclicity, have been an important part of his work for more
than twenty years.
ROBERT A. KOWATCH, M.D.
Professor of Psychiatry and Pediatrics
University of Cincinnati Medical Center
Director, Child and Adolescent Mood Disorders Program
Children’s Hospital Medical Center of Cincinnati
Cincinnati, Ohio
Dr. Kowatch received his medical degree in 1980 and completed
a residency in general psychiatry at the University of Pennsylvania Hospital in
Philadelphia. He completed a fellowship in child and adolescent psychiatry at
Hahnemann University in Philadelphia. He is board certified in general
psychiatry, child and adolescent psychiatry, and sleep disorders medicine.
In 1995, he was awarded an NIMH, Child and Adolescent Clinical
Mental Award which he completed at the University of Texas Southwestern Medical
Center at Dallas. In September of 2000 he moved to Cincinnati where he is a
professor of psychiatry and pediatrics at the University of Cincinnati Medical
Center and Children’s Hospital Medical Center.
His research interests are in the treatment of child and
adolescent bipolar disorders and the neurobiology of these disorders. He is the
principal coordinating investigator of a recently funded, NIMH, multi-site,
collaborative trial (1 RO1 MH63632-01) which is studying the efficacy of lithium
and sodium divalproex in bipolar children and adolescents. He also is studying
the neurobiology of affective lability of bipolar children and adolescents using
functional MRI and various affective probes.
DAVID J. KUPFER, M.D.
Thomas Detre Professor and Chairman
Department of Psychiatry
Professor of Neuroscience
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
David J. Kupfer, M.D., Thomas Detre Professor and Chairman of
the Department of Psychiatry and Professor of Neuroscience at the University of
Pittsburgh School of Medicine, received his bachelor (magna cum laude) and M.D.
degrees from Yale University. Following completion of an internship, Dr. Kupfer
continued his postgraduate clinical and research training at the Yale New Haven
Hospital and at the National Institute of Mental Health (NIMH). In 1969, he was
appointed an assistant professor of psychiatry at Yale University School of
Medicine. Dr. Kupfer joined the faculty at the University of Pittsburgh in 1973
as an associate professor of psychiatry and director of research and research
training at Western Psychiatric Institute and Clinic. He was promoted to
professor of psychiatry in 1975 and became chairman of the department in 1983.
As Thomas Detre Professor and Chairman of the Department of Psychiatry and
Director of Research at WPIC, he oversees the coordination and expansion of
investigations among the department's almost 200 faculty. He has promoted
widespread collaborations between clinical investigators in psychiatry and those
in more basic neurosciences. These studies are not limited to depression and
other mood disorders but encompass virtually every psychiatric disorder and
every age group, from infants to the "oldest old." Under Dr. Kupfer's direction,
WPIC has become one of the nation's preeminent university-based psychiatric
centers as evidenced by the quality and number of publications as well as the
amount of peer-reviewed federal funding for mental health research.
For more than twenty years, Dr. Kupfer's research has focused
primarily on the conceptualization, diagnosis, and treatment of mood disorders.
He has written more than 750 articles, books, and book chapters that examine the
use of medication in recurrent depression, the causes of depression, and the
relationship between biomarkers and depression.
In recognition of his contributions to the field, Dr. Kupfer
has been the recipient of numerous awards and honors including the A.E. Bennett
Research Award in Clinical Science (1975), the Anna-Monika Foundation Prize
(1977), the Daniel H. Efron Award (1979), the Twenty-Sixth Annual Award of the
Institute of Pennsylvania Hospital in Memory of Edward A. Strecker, M.D. (1989),
the William R. McAlpin, Jr. Research Achievement Award (1990), the 1993 American
Psychiatric Association Award for Research in Psychiatry, the First Isaac Ray
Decade of Excellence Award (1994), the Twelfth Annual Edward J. Sachar Award
(1996), the 1996 Gerald Klerman Lifetime Research Award (jointly with Dr. Ellen
Frank), the Institute of Medicine’s 1998 Rhoda and Bernard Sarnat International
Prize in Mental Health, and the American Psychopathological Association’s 1999
Joseph Zubin Award (jointly with Dr. Ellen Frank). He was elected to the
Institute of Medicine of the National Academy of Sciences in 1990.
FOUZIA LAGHRISSI-THODE, M.D.
CNS Director
New Medicine Strategy
F. Hoffmann-La Roche Ltd.
Pharmaceutical Division
Strategic Marketing and Business Development
Basel, Switzerland
Since 2000, Fouzia Laghrissi-Thode, M.D. holds, at F.
Hoffmann-La Roche (Basel, Switzerland) a CNS Leader Position in the New
Medicines Strategy Department. She also holds, since 1992, an appointment as an
Assistant Professor in Psychiatry at Western Psychiatric Institute and Clinic,
University of Pittsburgh Medical Center (USA). Prior to joining F. Hoffmann-La
Roche, she worked for three years in the International Clinical Research Nervous
System Department of Novartis Pharma (Basel, Switzerland). After graduating in
Medicine at the University of Tours (France) in 1987 and completing residencies
in General and Internal Medicine, she specialized in Psychiatry and received her
European certification in 1992. As a Principal Investigator she conducted a
number of studies in depressed elderly and medically ill patients, and actively
participated as co-investigator in the research conducted by the NIMH CRC for
the Study of Affective Disorders and Late Life Mood Disorders.
THOMAS P. LAUGHREN, M.D.
Team Leader, Psychiatric Drug Products
Division of Neuropharmacological Drug Products
Food and Drug Administration
Rockville, Maryland
Dr. Laughren is currently Team Leader for the Psychiatric Drug
Products Group in the Division of Neuropharmacological Drug Products, Center for
Drug Evaluation and Research at FDA. Prior to coming to FDA in September 1983,
Dr. Laughren was affiliated with the VA Medical Center in Providence, Rhode
Island, and was on the faculty of the Brown University Program in Medicine. He
received his medical degree from the University of Wisconsin in Madison,
Wisconsin, and he also completed residency training in psychiatry at the
University of Wisconsin. Dr. Laughren is board certified in general psychiatry.
BARRY D. LEBOWITZ, Ph.D.
Chief, Adult and Geriatric Treatment and
Preventive Interventions Research Branch
National Institute of Mental Health
Bethesda, Maryland
Dr. Barry Lebowitz is Chief of the Adult and Geriatric
Treatment and Preventive Interventions Research Branch of the National Institute
of Mental Health and an adjunct professor in the Department of Psychiatry of the
Georgetown University School of Medicine. A native of Boston, Massachusetts, Dr. Lebowitz is a graduate of McGill University and Cornell University. He was
elected a Fellow of the Gerontological Society of America and an Honorary Fellow
of the American Psychiatric Association and the American Association for
Geriatric Psychiatry. Dr. Lebowitz serves on the editorial boards of a number of
scientific and professional journals and is the author of many books and
articles in mental health and aging.
LYDIA LEWIS
Executive Director
National Depressive and Manic-Depressive Association
Chicago, Illinois
Lydia Lewis became Executive Director of the National
Depressive and Manic-Depressive Association (National DMDA) in June 1997. Her
primary responsibility is to position the organization as a leading resource for
patients, family members, professionals, legislators and the media who want (or
need) to know more about mood disorders and their treatments. Also serving as
spokesperson for the organization, Ms. Lewis has spoken at the invitation of
various organizations, including the American College of Neuropsychopharmacology,
the American Psychological Association, the American Psychiatric Association,
the Society for Biological Psychiatry, the National Institute of Mental Health,
Yale University School of Medicine and the National Foundation for Brain
Research. She is a member of the oversight committees of several large NIMH
clinical trials including STEP-BD, STAR*D, TADS and the hypericum (St. John’s
Wort) trials. In addition she was a charter member of the National Institutes of
Health Director’s Council of Public Representatives. She holds a Bachelor of
Arts in psychology from the State University of New York at Buffalo. One of her
proudest accomplishments has been her willingness to do life-long battle with
depression.
Top of Page
|
